UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report
Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Repros Therapeutics Inc.

Delaware (State or other jurisdiction of		001-15281 (Commission File Number)		76-0233274 (I.R.S. Employer Identification No.)
incorporation or organization)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01 — Other Events

     On June 5, 2009, Repros Therapeutics, Inc., the Company, issued a press release announcing the formation of its Scientific Advisory Board to provide guidance to the Company with the development program for its lead product, Proellex, which is under development for uterine fibroids and endometriosis, two gynecological disorders with high unmet medical needs. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The press release is incorporated herein by reference and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

Item 9.01 — Financial Statements and Exhibits

     (d) Exhibits

Exhibit
Number		Description
99.1		Press Release dated June 5, 2009

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXHIBIT INDEX

Exhibit
Number		Description
99.1		Press Release dated June 5, 2009